Biomea Fusion Inc. (BMEA), a clinical-stage biopharmaceutical company, expects to present data from its COVALENT-103 trial on December 9, 2024.
COVALENT-103 is a Phase I trial evaluating the company's drug candidate BMF-500 in adult patients with relapsed or refractory acute leukemia with FMS-like tyrosine kinase 3 (FLT3) wild-type and FLT3 mutations.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.